BR112017027951A2 - Brk prevention compound - Google Patents
Brk prevention compoundInfo
- Publication number
- BR112017027951A2 BR112017027951A2 BR112017027951-7A BR112017027951A BR112017027951A2 BR 112017027951 A2 BR112017027951 A2 BR 112017027951A2 BR 112017027951 A BR112017027951 A BR 112017027951A BR 112017027951 A2 BR112017027951 A2 BR 112017027951A2
- Authority
- BR
- Brazil
- Prior art keywords
- brk
- compound
- inhibitory compound
- brk inhibitory
- symbols
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015124315 | 2015-06-22 | ||
| JP2015-124315 | 2015-06-22 | ||
| PCT/JP2016/068429 WO2016208595A1 (ja) | 2015-06-22 | 2016-06-21 | Ｂｒｋ阻害化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017027951A2 true BR112017027951A2 (ja) | 2018-08-28 |
Family
ID=57584946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017027951-7A BR112017027951A2 (ja) | 2015-06-22 | 2016-06-21 | Brk prevention compound |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10377759B2 (ja) |
| EP (1) | EP3312182B9 (ja) |
| JP (1) | JP6819585B2 (ja) |
| KR (1) | KR20180015160A (ja) |
| CN (1) | CN107709327A (ja) |
| AU (1) | AU2016284402B2 (ja) |
| BR (1) | BR112017027951A2 (ja) |
| CA (1) | CA2990145A1 (ja) |
| ES (1) | ES2909048T3 (ja) |
| HK (1) | HK1250159A1 (ja) |
| IL (1) | IL256414A (ja) |
| MX (1) | MX2017016325A (ja) |
| PH (1) | PH12017502363A1 (ja) |
| RU (1) | RU2719477C2 (ja) |
| SG (1) | SG11201710604SA (ja) |
| WO (1) | WO2016208595A1 (ja) |
| ZA (1) | ZA201708699B (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190084063A (ko) | 2016-10-28 | 2019-07-15 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Ｅｚｈ２-매개성 암 치료용 조성물 및 방법 |
| US11541051B2 (en) | 2016-12-08 | 2023-01-03 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| ES2909234T3 (es) * | 2016-12-21 | 2022-05-05 | Ono Pharmaceutical Co | Compuestos de 6-amino-7,9-dihidro-8H-purin-8-ona como inhibidores de Brk |
| NZ766835A (en) | 2018-03-02 | 2023-09-29 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| CN112154146A (zh) | 2018-03-06 | 2020-12-29 | 西奈山伊坎医学院 | 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法 |
| CA3105121A1 (en) * | 2018-07-05 | 2020-01-09 | Icahn School Of Medicine At Mount Sinai | Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use |
| MX2021000795A (es) * | 2018-07-24 | 2021-04-12 | Taiho Pharmaceutical Co Ltd | Compuestos heterociclicos para inhibir la actividad de shp2. |
| BR112021022380A2 (pt) * | 2019-05-08 | 2022-03-22 | Vimalan Biosciences Inc | Inibidores de jak |
| JP2022544174A (ja) | 2019-08-08 | 2022-10-17 | ビマラン バイオサイエンシーズ，インク． | Ｊａｋ阻害剤 |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| CR20230057A (es) | 2020-07-02 | 2023-08-15 | Incyte Corp | Compuestos tríciclicos de urea como inhibidores de jak2 v617f |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| CN112830936B (zh) * | 2021-01-08 | 2022-01-28 | 广西师范大学 | 核黄素化合物、其制备方法及应用 |
| CA3211748A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| CN115466264A (zh) * | 2021-06-11 | 2022-12-13 | 腾讯科技（深圳）有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA200870385A1 (ru) | 2006-03-29 | 2009-04-28 | Фолдркс Фармасьютикалз, Инк. | Ингибирование токсичности альфа-синуклеина |
| SI2526933T1 (sl) * | 2006-09-22 | 2015-07-31 | Pharmacyclics, Inc. | Inhibitorji Bruton tirozin kinaze |
| EA201070572A1 (ru) * | 2007-11-07 | 2010-12-30 | Фолдркс Фармасьютикалз, Инк. | Модуляция транспорта белков |
| WO2009131687A2 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| WO2010014930A2 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Therapeutic agents |
| NZ630467A (en) * | 2013-01-16 | 2017-02-24 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
-
2016
- 2016-06-21 ES ES16814365T patent/ES2909048T3/es active Active
- 2016-06-21 JP JP2017524929A patent/JP6819585B2/ja active Active
- 2016-06-21 US US15/738,485 patent/US10377759B2/en active Active
- 2016-06-21 RU RU2017145026A patent/RU2719477C2/ru active
- 2016-06-21 WO PCT/JP2016/068429 patent/WO2016208595A1/ja active Application Filing
- 2016-06-21 AU AU2016284402A patent/AU2016284402B2/en not_active Ceased
- 2016-06-21 BR BR112017027951-7A patent/BR112017027951A2/ja not_active Application Discontinuation
- 2016-06-21 MX MX2017016325A patent/MX2017016325A/es unknown
- 2016-06-21 SG SG11201710604SA patent/SG11201710604SA/en unknown
- 2016-06-21 CA CA2990145A patent/CA2990145A1/en not_active Abandoned
- 2016-06-21 EP EP16814365.9A patent/EP3312182B9/en active Active
- 2016-06-21 CN CN201680037068.4A patent/CN107709327A/zh active Pending
- 2016-06-21 KR KR1020177036544A patent/KR20180015160A/ko unknown
-
2017
- 2017-12-19 PH PH12017502363A patent/PH12017502363A1/en unknown
- 2017-12-19 IL IL256414A patent/IL256414A/en unknown
- 2017-12-20 ZA ZA2017/08699A patent/ZA201708699B/en unknown
-
2018
- 2018-07-24 HK HK18109569.2A patent/HK1250159A1/zh unknown
-
2019
- 2019-06-27 US US16/455,016 patent/US11512087B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2017016325A (es) | 2018-03-02 |
| AU2016284402B2 (en) | 2020-04-02 |
| RU2017145026A3 (ja) | 2019-12-02 |
| JPWO2016208595A1 (ja) | 2018-04-05 |
| PH12017502363A1 (en) | 2018-06-25 |
| ES2909048T3 (es) | 2022-05-05 |
| CN107709327A (zh) | 2018-02-16 |
| EP3312182A1 (en) | 2018-04-25 |
| EP3312182B1 (en) | 2022-02-23 |
| US11512087B2 (en) | 2022-11-29 |
| SG11201710604SA (en) | 2018-01-30 |
| WO2016208595A1 (ja) | 2016-12-29 |
| US20180186800A1 (en) | 2018-07-05 |
| IL256414A (en) | 2018-02-28 |
| US20190315756A1 (en) | 2019-10-17 |
| RU2719477C2 (ru) | 2020-04-17 |
| EP3312182B9 (en) | 2022-06-29 |
| JP6819585B2 (ja) | 2021-01-27 |
| AU2016284402A1 (en) | 2018-01-18 |
| US10377759B2 (en) | 2019-08-13 |
| HK1250159A1 (zh) | 2018-11-30 |
| ZA201708699B (en) | 2018-11-28 |
| RU2017145026A (ru) | 2019-07-23 |
| CA2990145A1 (en) | 2016-12-29 |
| KR20180015160A (ko) | 2018-02-12 |
| EP3312182A4 (en) | 2018-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017027951A2 (ja) | Brk prevention compound | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| BR112019002576A2 (pt) | composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| BR112018008966A2 (pt) | compostos inibidores de jak quinase para o tratamento de doença respiratória | |
| MX2019002356A (es) | Compuestos de biarilo utiles como inmunomoduladores. | |
| BR112016023558A2 (pt) | compostos úteis como imunomoduladores | |
| BR112018007381A2 (pt) | compostos úteis como imunomoduladores | |
| BR112017020999A2 (pt) | inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| BR112018005932A2 (pt) | inibidores de isoindolinona da interação de mdm2-p53 que têm atividade anticâncer | |
| EA201990833A1 (ru) | Соединение пиридина | |
| CU20160020A7 (es) | Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer | |
| BR112014025711A2 (pt) | composto, medicamento, e, uso de um composto | |
| BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
| BR112017010311A2 (pt) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| UY36080A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
| BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
| BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
| PH12016502130A1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
| CL2019000661A1 (es) | Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica. | |
| MX2016013256A (es) | Compuestos antibacterianos. | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |